Search Results - "Freeman CL"

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.

Authors: Oswald LB Li X Gudenkauf LM et al.

Source: Bone marrow transplantation [Bone Marrow Transplant] 2026 Jul; Vol. 61 (7), pp. 864-872. Date of Electronic Publication: 2026 May 11.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease.

Authors: Abuhelwa Z Amisha F Fan W et al.

Source: Frontiers in oncology [Front Oncol] 2025 Oct 27; Vol. 15, pp. 1663814. Date of Electronic Publication: 2025 Oct 27 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Comprehensive Computational Assessment of Al-Based High-Entropy Superalloys: Thermodynamic, Mechanical, and Radiation Shielding Characterization for Nuclear Applications.

Authors: ALMisned, Ghada Güler, Ömer Özkul, İskender et al.

Source: JOM: The Journal of The Minerals, Metals & Materials Society (TMS); Oct2025, Vol. 77 Issue 10, p7592-7609, 18p

Genetic analysis of cell-free DNA in follicular lymphoma in comparison with tissue-derived DNA.

Authors: Hori, Yoshikazu Hosoi, Hiroki Osuga, Mitsuo et al.

Source: Leukemia & Lymphoma. Dec2025, Vol. 66 Issue 14, p2633-2643. 11p.

B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study.

Authors: Gu, Tingfei Chen, Zhao Wang, Tianyao et al.

Source: Journal of Hematology & Oncology. 11/14/2025, Vol. 18 Issue 1, p1-5. 5p.

The author replies.

Authors: Freeman CL

Source: Critical care medicine [Crit Care Med] 2014 Aug; Vol. 42 (8), pp. e604-5.

Publication Type: Letter; Comment

Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0355501 Publication Model: Print Cited Medium: Internet ISSN: 1530-0293 (Electronic) Linking ISSN: 00903493 NLM ISO Abbreviation: Crit Care Med Subsets: MEDLINE

Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.

Authors: Maura F Freeman CL Maclachlan KH et al.

Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Dec 11. Date of Electronic Publication: 2025 Dec 11.

Publication Type: Journal Article; Preprint

Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Following BCMA CAR T Failure.

Alternate Title: Tüm Zorluklara Rağmen: BCMA CAR T Tedavisi Başarısızlığını Takiben Sekonder Plazma Hücreli Lösemiye Dönüşen, Ultra Yüksek Riskli Nüks/Refrakter Multipl Miyelom Olgusunda Teclistamab ile Başarılı Kurtarma Tedavisi

Authors: Kazi, Bilal Abdallah, Al-Ola A. Patil, Vijay et al.

Source: Turkish Journal of Hematology. 2025, Vol. 42 Issue 4, p337-341. 5p.

Structural modulation, oriented growth of rock salt, and spinel in (Co(Cr/Mg)FeMnNi) multicomponent oxide and derivatives.

Authors: Mukherjee, Saptarshi Mukhopadhyay, N. K. Basu, Joysurya

Source: Journal of the American Ceramic Society; Sep2025, Vol. 108 Issue 9, p1-15, 15p

Order evolution from a high‐entropy matrix: Understanding and predicting paths to low‐temperature equilibrium.

Authors: Almishal, Saeed S. I. Miao, Leixin Tan, Yueze et al.

Source: Journal of the American Ceramic Society; Feb2025, Vol. 108 Issue 2, p1-13, 13p

Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature.

Authors: Gauci, Pierre-Alexis Cremoni, Marion Delotte, Jérôme et al.

Source: Renal Failure. Dec2025, Vol. 47 Issue 1, p1-8. 8p.

Drug repositioning for pan-cancers of the digestive system: Identification of amonafide and BX795 as potential therapeutics via integrative Omics analysis.

Authors: Liu, Weidong Gao, Jiaying Ren, Shuqiang et al.

Source: PLoS ONE. 6/16/2025, Vol. 20 Issue 6, p1-16. 16p.

Review of phase equilibria of the system BaO–TiO2.

Authors: Zaman, Tasmia Koshy, Pramod Daniels, John E. et al.

Source: Journal of the American Ceramic Society; Jun2025, Vol. 108 Issue 6, p1-38, 38p

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy.

Authors: Su, Wenyan Li, Jianyi Men, Jinzhao et al.

Source: Clinical Kidney Journal. May2025, Vol. 18 Issue 5, p1-10. 10p.

The excellent tunable performance of BaSnxTi1−xO3 ceramics at low electric field.

Authors: Zheng, Haoran Guo, Hailong Yang, Pan et al.

Source: Journal of Materials Science: Materials in Electronics; Jan2025, Vol. 36 Issue 1, p1-9, 9p

Enhanced electrical reliability of Zr‐doped BaTiO3 nanoceramics: First‐principle calculations and experimental studies.

Authors: Zhang, Weichen Cheng, Xu Zhen, Yichao et al.

Source: Journal of the American Ceramic Society; Apr2025, Vol. 108 Issue 4, p1-13, 13p

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting.

Authors: Hu, Yuhan Hou, Jiangxue Jiang, Zhongxing et al.

Source: Experimental Hematology & Oncology. 3/26/2025, Vol. 14 Issue 1, p1-4. 4p.

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.

Authors: Zheng, Huijian Xian, Huajian Zhang, Wenjie et al.

Source: Journal of Hematology & Oncology. 3/1/2025, Vol. 18 Issue 1, p1-4. 4p.

Safety assessment of obinutuzumab: Real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025.

Authors: Li, Xiangpeng Liang, Haonan Leng, Ping et al.

Source: PLoS ONE. 10/10/2025, Vol. 20 Issue 10, p1-20. 20p.

Desensitization in HLA-incompatible kidney transplant recipients: current strategies and emerging perspectives.

Authors: Altindal, Mahmut Guldan, Mustafa Ozbek, Lasin et al.

Source: Clinical Kidney Journal. Aug2025, Vol. 18 Issue 8, p1-15. 15p.